- Ahead of Phase 3 data readout in the second half of next year, Castle Creek Biosciences Inc CCBS seeks to make NASDAQ debut under the symbol CCBS.
- The Company's advanced product candidate, dabocemagene autoficel or D-Fi, is under development for recessive dystrophic epidermolysis bullosa, a rare disease caused by a lack of collagen in the skin resulting in uncontrollable blistering.
- It's a program that comes from the small acquisition of the biotech Fibrocell back in September 2019.
- The biotech plans to launch a second Phase 3 study in the second half of 2021 in the dominant version of dystrophic epidermolysis bullosa.
- Though Castle Creek did not divulge exact figures in its SEC paperwork, it's expected that a significant portion of these funds will go toward the two studies and "pre-commercial" activities for D-Fi.
- IPO prospectus filing here
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.